Clinical Trials Directory

Trials / Completed

CompletedNCT02358655

Canadian Community Utilization of Stroke Prevention Study - Emergency Department

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
360 (actual)
Sponsor
Population Health Research Institute · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Atrial fibrillation (AF) is a common heart condition, and increases the risk of stroke by six times. There are several medications (blood thinners) that can prevent strokes in AF patients. Many AF patients present to the emergency department, but about half of AF patients leave without prescription of a blood thinner. The study aims to evaluate if adding options like giving a patient education kit, encouraging emergency room physicians to prescribe a blood thinner and providing a specialized AF clinic to patients will increase the number patients receiving blood thinners to prevent strokes.

Detailed description

This is a knowledge translation study will occur in three consecutive phases: Phase 1 is a retrospective chart review of all patients who presented to the emergency department (ED) with ECG documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants (OACs) were prescribed for eligible AF patients at ED discharge. In Phase 2 a low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term OAC prescription, and a follow-up letter to the patient's family physician. After a one month transition phase, a high intensity intervention will be applied during 6 months in Phase 3. Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.

Conditions

Interventions

TypeNameDescription
OTHERRetrospective review of OAC prescription
OTHERPrescription of OAC in ED
OTHERCommunity AF clinic

Timeline

Start date
2015-06-01
Primary completion
2016-10-31
Completion
2018-03-08
First posted
2015-02-09
Last updated
2018-10-09

Locations

5 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT02358655. Inclusion in this directory is not an endorsement.